Morgan Stanley upgraded Immuneering to Equal Weight from Underweight with a price target of $14, up from $5. The company accelerated timelines for its Phase 1 study with a recommended Phase 2 dose expected by early 2024, the analyst tells investors in a research note. The firm cites "encouraging" initial results and greater clarity on the timing of upcoming catalysts for the upgrade.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMRX:
- Immuneering Picks Up New Kudos but Still Falters
- Immuneering price target raised to $22 from $18 at Chardan
- Immuneering Announces $30 Million Underwritten Offering
- Immuneering prices 2.73M share underwritten offering at $11 per share
- Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104